Small Molecule Injectable Drugs Market Report 2025

The small molecule injectable drugs market size has grown rapidly in recent years. It will grow from $219.57 billion in 2024 to $245.97 billion in 2025 at a compound annual growth rate (CAGR) of 12%. The growth in the historic period can be attributed to rising chronic diseases, aging population, government initiatives, increasing healthcare expenditure, improved manufacturing processes.

The small molecule injectable drugs market size is expected to see rapid growth in the next few years. It will grow to $379.15 billion in 2029 at a compound annual growth rate (CAGR) of 11.4%. The growth in the forecast period can be attributed to personalized healthcare, digital health integration, supply chain optimization, real-world evidence utilization, shift towards outpatient care. Major trends in the forecast period include advancements in drug delivery systems, technological advancements, focus on research and development, innovation in injectable therapies, fast-track approvals of new drug formulation.

The forecast of 11.4% growth over the next five years reflects a modest reduction of 1.2% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff increases could impact U.S. hospital pharmacies by inflating costs of sterile lyophilized products and ready-to-use injectable formulations manufactured in Spain and France, resulting in limited critical care medication availability and higher treatment costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The escalating prevalence of chronic diseases is anticipated to drive significant growth in the small-molecule injectable drug market in the foreseeable future. Chronic diseases, characterized by prolonged persistence and gradual progression, are on the rise due to factors such as sedentary lifestyles, unhealthy dietary habits, tobacco use, and increasing stress levels. These lifestyle choices contribute to the emergence of conditions such as obesity, diabetes, cardiovascular diseases, and certain cancers. Small-molecule injectable drugs play a pivotal role in managing chronic diseases by providing targeted therapy, enhanced compliance, disease modification, combination therapy options, and opportunities for therapeutic monitoring. For instance, according to the World Health Organization's data in September 2023, non-communicable diseases (NCDs) or chronic diseases accounted for 74% of the 41 million global deaths annually. Among these, 17.9 million were due to cardiovascular diseases, 9.3 million to cancer, 4.1 million to chronic respiratory diseases, and 2 million to diabetes, underscoring the driving force behind the growth of the small-molecule injectable drug market.

Companies operating in the small-molecule injectable drug market are concentrating on advancing new technologies, such as microparticle technology, to enhance the solubility of active pharmaceutical ingredients in oral drug products. Microparticle technology involves the design, fabrication, and application of particles at the microscale level, typically ranging from nanometers to micrometers in size, using various materials such as polymers, metals, ceramics, and composites. For example, in March 2022, Evonik Industries AG, a Germany-based specialty chemicals company, introduced EUDRATEC SoluFlow, a novel microparticle technology aimed at improving the solubility of active pharmaceutical ingredients in oral drug products. This innovative emulsion-based process technology addresses solubility challenges faced by traditional manufacturing methods, particularly for new small-molecule therapeutics where over 70% of compounds are insoluble. EUDRATEC SoluFlow facilitates the development of new oral therapeutics across various therapeutic areas, including cancer, cardiovascular diseases, infectious diseases, and diabetes, by converting poorly soluble drugs into free-flowing powders of amorphous solid dispersions (ASD).

In April 2023, Delpharm SAS, a France-based drug developer and contract manufacturer, acquired the Leiden Development Centre in the Netherlands from Dr. Reddy's Laboratories for an undisclosed sum. This acquisition supports Delpharm's strategy to expand its pharmaceutical development services, particularly in injectable formulations. Delpharm aims to offer a comprehensive one-stop shop service for clients seeking to develop injectable drugs, thereby accelerating the availability of new medicines for patients. Dr. Reddy's Laboratories, an India-based pharmaceutical company, has been providing small-molecule injectable drug formulations through the Leiden Development Centre.

Major companies operating in the small molecule injectable drugs market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, Fresenius Kabi AG, GlaxoSmithKline plc, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Becton Dickinson and Company, Teva Pharmaceutical Industries Ltd., Baxter International Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Limited, Hikma Pharmaceuticals plc, BioCryst Pharmaceuticals Inc., Mylan N.V.

North America was the largest region in the small molecule injectable drugs market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the small molecule injectable drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the small molecule injectable drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The small molecule injectable drugs market consists of sales of antineoplastic agents, hormones, and vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment - many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The small molecule injectable drugs market research report is one of a series of new reports that provides small molecule injectable drugs market statistics, including small molecule injectable drugs industry global market size, regional shares, competitors with a small molecule injectable drugs market share, detailed small molecule injectable drugs market segments, market trends and opportunities, and any further data you may need to thrive in the small molecule injectable drugs industry. This small-molecule injectable drug market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Small molecule injectable drugs refer to pharmaceutical substances characterized by their small size and low molecular weight. These medications are typically administered via injection, including intravenous, intramuscular, or subcutaneous routes, to ensure systemic distribution throughout the body.

The primary types of drug classes within small-molecule injectable drugs encompass small-molecule antibiotics, analgesics, chemotherapy agents, antivirals, anticoagulants, skeletal muscle relaxants, anticonvulsants, and others. Small-molecule antibiotics, for instance, are antibacterial medications featuring a low molecular weight and simple chemical structure. These drugs find applications across various medical indications such as pain management, oncology, infectious diseases, cardiovascular diseases, central nervous system (CNS) disorders, among others. Delivery of small-molecule injectable drugs encompasses various methods including IV sets, intravenous injections, infusion pumps, intramuscular injections, and subcutaneous injections. These delivery modalities cater to diverse end-users including hospitals, ambulatory clinics, outpatient facilities, infusion therapy centers, home care settings, and others.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.